128 related articles for article (PubMed ID: 2288316)
1. [Clinical study of estramustine phosphate disodium (Estracyt) on prostatic cancer--results of long-term therapy for 38 patients with prostatic cancer].
Asakawa M; Wada S; Hayahara N; Yayumoto R; Kishimoto T; Maekawa M; Morikawa Y; Kawakita J; Umeda M; Horii A
Hinyokika Kiyo; 1990 Nov; 36(11):1361-9. PubMed ID: 2288316
[TBL] [Abstract][Full Text] [Related]
2. [The phase IV studies with Estracyt in prostatic cancer--supplementary report: results of long-term therapy].
Ohhori T; Kubo T; Kawamura S; Suzuki T; Yagihashi Y; Kudo T; Tsuchida S; Harada T; Sasaki S; Orikasa S
Hinyokika Kiyo; 1992 Aug; 38(8):979-87. PubMed ID: 1414749
[TBL] [Abstract][Full Text] [Related]
3. [Clinical effects of estramustine phosphate disodium (Estracyt) on prostatic cancer].
Nishio S; Kishimoto T; Maekawa M; Kawakita J; Hayahara N; Yuki K; Morikawa Y; Yasumoto R; Kato Y; Funai K
Hinyokika Kiyo; 1986 Nov; 32(11):1763-70. PubMed ID: 3825823
[TBL] [Abstract][Full Text] [Related]
4. [The phase IV studies with Estracyt in prostatic cancer].
Ohhori T; Kubo T; Akasaka T; Funyu T; Yagihashi Y; Kudo T; Tsuchida S; Harada T; Sasaki S; Orikasa S
Hinyokika Kiyo; 1988 Aug; 34(8):1493-502. PubMed ID: 3057833
[TBL] [Abstract][Full Text] [Related]
5. [The evaluation of the effect of Estracyt on prostatic cancer].
Fukuoka H; Ishibashi Y; Sakai N; Ogawa T; Satomi Y; Sugawara T; Kamimura H; Yamaguchi T; Kishida K; Shirai K
Hinyokika Kiyo; 1991 Jan; 37(1):91-7. PubMed ID: 2011974
[TBL] [Abstract][Full Text] [Related]
6. Continuous versus intermittent oral therapy with estramustine phosphate (Estracyt).
Vahlensieck W; Wegner G
Scand J Urol Nephrol Suppl; 1980; 55():147-9. PubMed ID: 6938018
[TBL] [Abstract][Full Text] [Related]
7. [Clinical studies on serum lipids in the patients with tumor of the prostate gland. 2nd. Report. Changes of serum lipids and lipoprotein fractions during the treatment of estramustine phosphate disodium, hexestrol and diethylstilbestrol 4, 4-diphosphoric ester for the patients with prostatic cancer (author's transl)].
Yoshida H; Shimada M
Nihon Hinyokika Gakkai Zasshi; 1980 Jan; 71(1):59-69. PubMed ID: 6155501
[TBL] [Abstract][Full Text] [Related]
8. [Clinical study of estramustine phosphate (Estracyt) on prostatic cancer].
Murase T; Mitsuya H; Honda N; Fukatu H; Aota Y; Shinoda M; Yoshida K; Sobajima T; Ohishi M; Tsumura Y
Hinyokika Kiyo; 1989 Jan; 35(1):179-85. PubMed ID: 2729015
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of advanced carcinoma of the prostate with estramustine phosphate (estracyt)].
Lancina Martín JA; Chantada Abal V; Lamas Meilan AC; González Martín M
Actas Urol Esp; 1984; 8(5):399-402. PubMed ID: 6524487
[No Abstract] [Full Text] [Related]
10. New steroidal alkylating agents in advanced stage D carcinoma of the prostate.
Mittelman A; Catane R; Murphy GP
Cancer Treat Rep; 1977; 61(2):307-10. PubMed ID: 872134
[TBL] [Abstract][Full Text] [Related]
11. [Stage D1 prostatic cancer benefited by a single regimen of Estracyt].
Hata M
Gan To Kagaku Ryoho; 1988 May; 15(5):1787-90. PubMed ID: 3369873
[TBL] [Abstract][Full Text] [Related]
12. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
Mackler NJ; Dunn RL; Hellerstedt B; Cooney KA; Fardig J; Olson K; Pienta KJ; Smith DC
Cancer; 2006 Jun; 106(12):2617-23. PubMed ID: 16691618
[TBL] [Abstract][Full Text] [Related]
13. [Value of estramustine phosphate in the treatment of estrogen-resistant prostatic adenocarcinoma].
Toulouse J; Jung JL; Bittard M
J Urol (Paris); 1984; 90(1):27-33. PubMed ID: 6725973
[TBL] [Abstract][Full Text] [Related]
14. [Total remission of prostatic cancer following treatment with Estracyt].
Romics I
Orv Hetil; 1982 Jan; 123(5):287-9. PubMed ID: 7063244
[No Abstract] [Full Text] [Related]
15. [Estracyt therapy in advanced prostate cancer: current status and personal results].
Nagel R; Leistenschneider W
Urologe A; 1983 May; 22(3):162-6. PubMed ID: 6683899
[TBL] [Abstract][Full Text] [Related]
16. Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial.
Meluch AA; Greco FA; Morrissey LH; Raefsky EL; Steis RG; Butts JA; Hainsworth JD;
Cancer; 2003 Nov; 98(10):2192-8. PubMed ID: 14601089
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacology and metabolism of a new therapeutic drug for prostatic cancer "Estracyt"].
Yamanaka H; Shida K
Gan To Kagaku Ryoho; 1984 Mar; 11(3):537-44. PubMed ID: 6422861
[TBL] [Abstract][Full Text] [Related]
18. Experiences with estramustine phosphate (Estracyt, Emcyt) in prostate cancer.
Murphy GP; Slack NH; Mittelman A
Semin Oncol; 1983 Sep; 10(3 Suppl 3):34-42. PubMed ID: 6364365
[No Abstract] [Full Text] [Related]
19. Palliative treatment with oral Estracyte in disseminated prostatic carcinoma.
Welvaart K
Arch Chir Neerl; 1975; 27(3):193-8. PubMed ID: 55103
[TBL] [Abstract][Full Text] [Related]
20. [Intermittent oral hormonal chemotherapy using estramustine phosphate and etoposide for the treatment of hormone-refractory prostate cancer].
Kimura M; Sasagawa T; Tomita Y; Katagiri A; Morishita H; Saito T; Tanikawa T; Kawasaki T; Saito K; Nishiyama T; Kasahara T; Hara N; Takahashi K
Hinyokika Kiyo; 2003 Dec; 49(12):709-14. PubMed ID: 14978952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
